Savara Inc (NASDAQ:SVRA) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC trimmed its holdings in Savara Inc (NASDAQ:SVRA) by 22.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,483 shares of the company’s stock after selling 4,709 shares during the period. AQR Capital Management LLC’s holdings in Savara were worth $66,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Savara during the 1st quarter worth about $35,000. Choreo LLC acquired a new stake in shares of Savara during the 2nd quarter worth about $59,000. DRW Securities LLC acquired a new stake in shares of Savara during the 2nd quarter worth about $62,000. Principal Financial Group Inc. boosted its stake in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares during the last quarter. Finally, Profund Advisors LLC acquired a new stake in shares of Savara during the 2nd quarter worth about $105,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Stock Performance

Savara stock opened at $3.76 on Friday. The company has a market cap of $519.59 million, a PE ratio of -10.16 and a beta of 0.96. The company has a fifty day moving average price of $4.18 and a two-hundred day moving average price of $4.36. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. Savara Inc has a 12 month low of $3.12 and a 12 month high of $5.70.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Research analysts expect that Savara Inc will post -0.44 earnings per share for the current year.

Wall Street Analyst Weigh In

SVRA has been the topic of several research analyst reports. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Savara in a report on Tuesday, October 8th. Oppenheimer raised their price target on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, June 26th. Finally, Guggenheim raised their price target on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $11.17.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.